Company: CERO
Filing Date: 2025-02-05
Form Type: S-1/A
Source: 0001213900-25-010230
Chunk: 259

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-05
Form: S-1/A
Chunk 259
---
 PIPE Financings In February 2024, we issued and sold an aggregate of 10,039 shares of Series A Preferred Stock, 6,127 Series A Warrants and 2,500 Preferred Warrants, at a price of $1,000 per share of Series A Preferred Stock, for aggregate cash proceeds of approximately $8.0 million, plus additional cash proceeds of up to $2.0 million if the Preferred Warrants are exercised. The following table summarizes the shares of our Series A Preferred Stock issued to our related parties:

| Purchasers(1)                           |     | Shares of Series A  Preferred Stock |       |     | Total    
 Purchase 
 Price    |           |
|:----------------------------------------|:----|:------------------------------------|------:|:----|:---------|----------:|
| Daniel Corey(2)                         |     |                                     |   150 |     | $        |   150,000 |
| Atwood-Edminster Trust dtd 4-2-2000 (3) |     |                                     | 1,002 |     | $        | 1,002,000 |
| Chris Ehrlich(4)                        |     |                                     |   275 |     | $        |   275,000 |
| Phoenix Biotech Sponsor, LLC(5)         |     |                                     | 1,380 |     | $        | 1,380,000 |

| (1) | Additional details regarding these stockholders and their equity holdings are included in this prospectus under the section “Principal Stockholders.” |

| (2) | Daniel Corey served as the Chief Technology Officer and a member of the board of directors from February 2024 to September 2024, and previously served as Chief Executive Officer, Chief Scientific Officer, and a member of the board of directors of Legacy CERo until the closing of the Business Combination in February 2024. |

| (3) | Brian G. Atwood served as Chairman and Chief Executive Officer from February 2024 to September 2024, and previously served as Chairman of PBAX until the closing of the Business Combination in February 2024 Mr. Atwood is a member of the board of directors and serves as a trustee of Atwood-Edminster Trust dtd 4-2-2000. |

| (4) | Chris Ehrlich has served as the Chairman and Chief Executive Officer since December 2024, and previously served as (i) interim